Expert Medical Societies Release Multidisciplinary Recommendations for Breast Cancer Patient Care During COVID-19 Pandemic

The American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Cancer Network (NCCN), the Commission on Cancer (CoC) of the American College of Surgeons, and the American College of Radiology® (ACR®) have released new joint recommendations for prioritization, treatment and triage of breast cancer patients during the coronavirus (COVID-19) pandemic.

“As hospital resources and staff become limited, it is vital to define which breast cancer patients require urgent care and which can have delayed or alternative treatment without changing survival or risking exposure to the virus,” said Jill R. Dietz, MD, FACS, president of the ASBrS.

“The COVID-19 pandemic presents unprecedented challenges. These guidelines can help modify patient care to minimize exposure risk and preserve resources for patients with the most immediate need for care,” said Lawrence N. Shulman, MD, chair of the CoC.

The new recommendations categorize these patients into priority levels (A, B, C) for urgency of care across all specialties and provide treatment recommendations for each category.

  • Priority A patients have conditions that are immediately life-threatening or symptomatic, requiring urgent treatment
  • Priority B patients have conditions that do not require immediate treatment but should start treatment before the pandemic is over
  • Priority C patients have conditions for which treatment can be safely deferred until the pandemic is over

“Implementation of these recommendations, based on the highest level of available evidence, must be adapted to current resource availability and COVID-19 pandemic severity in that region,” said Scott H. Kurtzman, MD, FACS, chair of the NAPBC.

Doctors should use the recommendations to prioritize care for these patients and adapt treatment recommendations to the local context at their hospital,” said William J. Gradishar, MD, chair of the NCCN breast cancer panel.

Access the new joint breast cancer patient care recommendations here.

Note: These new recommendations are presented in an article entitled, “Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic,” recently accepted for publication in an upcoming issue of Breast Cancer Research and Treatment, a peer-reviewed journal.  The link to the open access document will be provided when it is released.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”